Nuvectra Corp (NASDAQ:NVTR) shares traded down 6.1% on Friday . The company traded as low as $3.63 and last traded at $3.71. 496,837 shares changed hands during trading, an increase of 82% from the average session volume of 272,897 shares. The stock had previously closed at $3.95.

A number of equities research analysts have weighed in on the stock. BidaskClub downgraded shares of Nuvectra from a “hold” rating to a “sell” rating in a research note on Tuesday, February 26th. Raymond James decreased their price target on shares of Nuvectra from $23.00 to $18.00 and set an “outperform” rating on the stock in a research note on Friday, March 1st. JMP Securities reduced their target price on shares of Nuvectra from $26.00 to $18.00 and set an “outperform” rating on the stock in a research note on Thursday, May 2nd. They noted that the move was a valuation call. Finally, ValuEngine downgraded shares of Nuvectra from a “hold” rating to a “sell” rating in a research note on Friday, May 3rd. Two research analysts have rated the stock with a sell rating and five have given a buy rating to the company. Nuvectra presently has a consensus rating of “Hold” and a consensus target price of $20.40.

The company has a debt-to-equity ratio of 0.56, a quick ratio of 6.07 and a current ratio of 6.60.

Nuvectra (NASDAQ:NVTR) last issued its earnings results on Wednesday, May 1st. The company reported ($0.83) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by ($0.18). Nuvectra had a negative net margin of 98.77% and a negative return on equity of 62.18%. The firm had revenue of $11.13 million during the quarter, compared to analyst estimates of $12.76 million. On average, research analysts forecast that Nuvectra Corp will post -3.17 earnings per share for the current fiscal year.

In other news, Director David D. Johnson bought 20,000 shares of Nuvectra stock in a transaction dated Monday, May 6th. The shares were bought at an average price of $6.12 per share, for a total transaction of $122,400.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Benjamin Tranchina bought 8,500 shares of Nuvectra stock in a transaction dated Wednesday, May 22nd. The stock was purchased at an average price of $4.25 per share, for a total transaction of $36,125.00. The disclosure for this purchase can be found here. 2.90% of the stock is currently owned by insiders.

Institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA bought a new position in shares of Nuvectra in the first quarter valued at about $40,000. PNC Financial Services Group Inc. raised its holdings in shares of Nuvectra by 231.8% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,318 shares of the company’s stock valued at $54,000 after buying an additional 2,318 shares during the last quarter. Thompson Siegel & Walmsley LLC bought a new position in shares of Nuvectra in the first quarter valued at about $64,000. Metropolitan Life Insurance Co. NY raised its holdings in shares of Nuvectra by 356.5% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 5,108 shares of the company’s stock valued at $83,000 after buying an additional 3,989 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Nuvectra by 89.4% in the first quarter. JPMorgan Chase & Co. now owns 8,375 shares of the company’s stock valued at $92,000 after buying an additional 3,954 shares during the last quarter. 81.14% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This news story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2019/06/16/nuvectra-nasdaqnvtr-stock-price-down-6-1.html.

About Nuvectra (NASDAQ:NVTR)

Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs.

Further Reading: What is intrinsic value?

Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.